Path less traveled

Taking a cue from the Spanish conquistador, Coronado Biosciences Inc. has chosen the path less traveled on its way to securing a public listing. The natural immunotherapy company filed a Form 10-12G with SEC last month in preparation to begin listing on the OTC Bulletin Board in late September. But is not planning to raise any money.

The company has raised over $60 million, including $25.8 million in a series C round in early July that should fund operations into early 2013, according to President and CEO Bobby Sandage...